Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant

M. Eapen, S. A. Giralt, M. M. Horowitz, J. P. Klein, J. E. Wagner, M. J. Zhang, M. S. Tallman, D. I. Marks, B. M. Camitta, R. E. Champlin, O. Ringdén, C. N. Bredeson, R. Martino, R. P. Gale, M. S. Cairo, M. R. Litzow, M. deLima

Research output: Contribution to journalArticlepeer-review

196 Scopus citations


Treatment options for persons with leukemia relapsing after allogeneic transplantation are limited. We analyzed the outcome of 279 patients with acute and chronic leukemia, who relapsed after HLA-identical sibling transplantation and received a second allogeneic transplant. The influence of potential risk factors on treatment-related mortality (TRM), relapse, treatment failure (relapse or death) and overall survival after second transplantation were assessed using proportional-hazards regression. The cumulative incidences (95% confidence interval) of relapse and TRM at 5 years were 42 (36-48)% and 30 (24-36)%, respectively. The 5-year probabilities of both overall and leukemia-free survival were 28 (23-34)%. In multivariate analyses, risks of treatment failure and mortality were lower in younger patients (≤20 years) and patients who relapsed after 6 months from first transplantation. Risks of relapse were lower in patients who relapsed after 6 months from first transplantation and in complete remission prior to second transplantation. Risks of relapse were higher after reduced-intensity conditioning regimens. Any potential advantage of using a different matched related donor for a second transplantation is not supported by these data. Although age, disease status and conditioning regimen are important, duration of remission after first transplantation appear to be the most important determinant of outcome.

Original languageEnglish (US)
Pages (from-to)721-727
Number of pages7
JournalBone marrow transplantation
Issue number8
StatePublished - 2004

Bibliographical note

Funding Information:
This work was supported by a Clinical Research Career Development Award from the American Society of Clinical Oncology (ME), Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the National Heart, Lung and Blood Institute and the Cancer Center, Medical College of Wisconsin.


  • Duration of remission
  • Leukemia
  • Matched related donor
  • Reduced-intensity conditioning regimen
  • Second transplantation


Dive into the research topics of 'Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant'. Together they form a unique fingerprint.

Cite this